|Bid||0.3350 x N/A|
|Ask||0.3400 x N/A|
|Day's range||0.3250 - 0.3450|
|52-week range||0.1350 - 0.4500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BRISBANE, Australia, November 29, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) ("Sonic") has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Micr
BRISBANE, Australia, October 27, 2022--SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.
BRISBANE, Australia, May 26, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") has signed a strategic partnership agreement ("Agreement") with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.